Clinical Trials Sponsored by Kirby Institute

Total 74050 results

Kirby Institute

Recruiting

The National Australian HCV Point-of-Care Testing Program - Minimal Dataset

Hepatitis C

Australia
Kirby Institute

Recruiting

Evaluation of Hepatitis B Virus (HBV) DNA Test as Point of Care Tool (HBVPOCT)

Hepatitis B

Australia
Kirby Institute

Recruiting

Real World Assessment of People Living With Chronic Hepatitis B in Australia (REACH-B)

Hepatitis B

Australia
Kirby Institute

Recruiting

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (TOPIC)

Hepatitis C | Liver Cirrhoses | Liver Inflammation

Australia
Kirby Institute

Completed

Expanded PrEP Implementation in Communities in NSW (EPIC-NSW)

HIV | STI

Australia
Kirby Institute

Terminated

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs (DARLO-C)

Hepatitis C

Australia
Kirby Institute

Completed

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients (SMART-C)

Hepatitis C, Chronic

United States, United Kingdom, Australia, France, New Zealand, Canada, Switzerland, Germany
Kirby Institute

Completed

Study of the Prevention of Anal Cancer (SPANC)

Cancer | Human Papillomavirus

Australia
Kirby Institute

Completed

Bone and Body Comp: A Sub Study of the SECOND-LINE Study

HIV

Malaysia, South Africa, Argentina, India, Thailand
Kirby Institute

Completed

MARCH Renal Substudy (MARCHrenal)

Proteinuria | HIV

Canada, Australia, Germany, Argentina, Japan, Thailand, United Kingdom, Mexico
Kirby Institute

Not yet recruiting

PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised. (PATH)

Invasive Fungal Infections | Infection, Bacterial | Infection, Fungal | Injection Site Infection | Infection, Soft Tissue | Invasive Bacterial Infection
Kirby Institute

Recruiting

Australian Hepatitis and Risk Survey in Prisons (AusHep)

HIV Infections | Hepatitis B | Hepatitis C

Australia
Kirby Institute

Not yet recruiting

The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

Hepatitis C

Australia
Kirby Institute

Recruiting

Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs (TEMPO)

Hepatitis C | Hepatitis C, Chronic

Australia
Kirby Institute

Recruiting

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)

Hepatitis C

Australia
Kirby Institute

Active, not recruiting

Body Composition Sub-study of the D2EFT Trial

HIV Infections

Malaysia, Zimbabwe, India, South Africa, Thailand
Kirby Institute

Completed

A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams (TEMPO)

Hepatitis C

Australia
Kirby Institute

Completed

Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings (SHARP-C)

Hepatitis C, Chronic

Australia
Kirby Institute

Active, not recruiting

Study of Pomalidomide in Anal Cancer Precursors (SPACE)

High Grade Squamous Intra-epithelial Lesion (HSIL)

Australia
Kirby Institute

Withdrawn

Evaluation of Novel Point of Care Hepatitis B Diagnostic Assays

Hepatitis B

Australia
Kirby Institute

Terminated

Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients (HSCT-HIV)

HIV-1 Infection

Australia
Kirby Institute

Completed

Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults. (ENCORE1)

HIV Infections

Australia
Kirby Institute

Completed

Surveillance and Treatment of Prisoners With Hepatitis C (SToP-C)

Hepatitis C

Australia
Kirby Institute

Completed

PrEP Demonstration Project (PRELUDE Study) (PRELUDE)

HIV

Australia
Kirby Institute

Completed

DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (DARE-C II)

Hepatitis C

Australia, New Zealand
Kirby Institute

Completed

Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response (CORAL)

HIV Infections
Kirby Institute

Completed

Raltegravir and Atazanavir Dosing Strategy Study (SPARTA)

HIV Infection

Australia
Kirby Institute

Completed

Hepatitis B Acceptability and Vaccination Incentive Trial (HAVIT)

Hepatitis B

Australia
Kirby Institute

Not yet recruiting

Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (OPTIMAR)

HIV Infections | Weight Gain
Kirby Institute

Recruiting

The National Australian HCV Point-of-Care Testing Program

Hepatitis C

Australia
Kirby Institute

Not yet recruiting

A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs (AMPLIFY)

Hepatitis C, Chronic
Kirby Institute

Recruiting

Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales (COSiN)

COVID

Australia
Kirby Institute

Completed

Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting (SHARP-P)

Hepatitis C, Chronic

Australia
Kirby Institute

Completed

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. (REACT)

Hepatitis C

Australia, United States, United Kingdom, New Zealand, Switzerland, Canada, Germany, Netherlands
Kirby Institute

Active, not recruiting

Control and Elimination Within Australia of Hepatitis C From People Living With HIV (CEASE)

Hepatitis C | HIV | HIV-HCV Coinfection

Australia
Kirby Institute

Completed

A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection (D3FEAT)

Hepatitis C, Chronic

Australia
Kirby Institute

Completed

A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use (SIMPLIFY)

Hepatitis C

Australia
Kirby Institute

Completed

MARCH Vascular Endothelium Substudy (MARCH VE)

Cardiovascular Disease

Argentina, Australia, Germany, Thailand
Kirby Institute

Completed

MARCH Central Nervous System Substudy

HIV-1 Infection

Argentina, Thailand, United Kingdom
Kirby Institute

Completed

Treatment of Recently Acquired Hepatitis C Virus Infection (ATAHC-II)

Acute Hepatitis C

Australia
Kirby Institute

Completed

A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study

HIV Infections

Australia
Kirby Institute

Completed

Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses. (ENCORE3)

Acquired Immunodeficiency Syndrome

United Kingdom
Kirby Institute

Completed

Pharmacokinetics of Lamivudine at Two Different Doses (ENCORE2)

HIV Infections

United Kingdom
Kirby Institute
AbbVie

Completed

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (TARGET3D)

Hepatitis C, Acute

United Kingdom, Australia, New Zealand
Kirby Institute
Celgene

Active, not recruiting

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia
Kirby Institute
Griffith University

Active, not recruiting

Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men (GoGoVax)

Neisseria Gonorrheae Infection

Australia
Kirby Institute
Janssen-Cilag Ltd.

Completed

DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) (DARE-C)

Hepatitis C, Chronic

Australia
Kirby Institute
Bristol-Myers Squibb

Withdrawn

Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism (HEPCOG-II)

Hepatitis C, Chronic

Australia
Kirby Institute
Pfizer; ViiV Healthcare

Completed

Maraviroc Switch Collaborative Study (MARCH)

HIV

Spain, Australia, Ireland, Mexico, Germany, Argentina, Canada, Chile, France, Japan, Poland, Thailand, United Kingdom
Kirby Institute
Imperial College London

Completed

The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1 (ENCORE1-CNS)

HIV Infection

Thailand, Germany, United Kingdom

3

Subscribe